| golidocitinib (DZD4205) / Dizal Pharma |
NCT06511869: AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) |
|
|
| Active, not recruiting | 2 | 130 | RoW | AZD4205 | Dizal Pharmaceuticals | Peripheral T-cell Lymphoma | 03/25 | 03/26 | | |
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) |
|
|
| Recruiting | 2 | 150 | RoW | AZD4205 | Dizal Pharmaceuticals | Peripheral T Cell Lymphoma | 05/25 | 12/26 | | |
NCT06295432: A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) |
|
|
| Recruiting | 2 | 90 | RoW | DZD9008+AZD4205, Inapplicable | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 06/25 | 06/25 | | |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
JACKPOT33, NCT06198907: Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) |
|
|
| Not yet recruiting | 2 | 69 | RoW | Golidocitinib, Sintilimab, platinum doublet chemotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Dizal Pharmaceuticals | Non-Small-Cell Lung Cancer | 12/26 | 12/27 | | |
NCT06573138: Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL |
|
|
| Not yet recruiting | 2 | 18 | NA | Selinexor, anti-PD-1 antibody plus Golidocitinib | Ruijin Hospital | Lymphoma, Extranodal NK-T-Cell | 07/27 | 07/27 | | |
| Not yet recruiting | 2 | 47 | RoW | Golidocitinib, Benmelstobart | Sun Yat-sen University | Natural Killer T-cell Lymphoma | 12/26 | 12/28 | | |
| Not yet recruiting | 2 | 7 | NA | Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone), Golidocitinib | Ruijin Hospital | Enteropathy Associated T Cell Lymphoma | 05/26 | 12/27 | | |
NCT06630091: A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study |
|
|
| Not yet recruiting | 2 | 30 | US | Golidocitinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone | M.D. Anderson Cancer Center | Peripheral T Cell Lymphoma | 07/27 | 07/29 | | |
| Recruiting | 2 | 45 | RoW | Golidocitinib, AZD4205, DZD4205, CHOP Regimen, Cyclophosphamide, doxorubicin, vincristine, prednisone | Henan Cancer Hospital | Peripheral T Cell Lymphoma | 07/25 | 07/26 | | |
NCT06739265: Golidocitinib Plus CHOP in Newly Diagnosed PTCL |
|
|
| Recruiting | 1/2 | 68 | RoW | Golidocitinib plus CHOP | Peking Union Medical College Hospital | Peripheral T-cell Lymphoma | 09/26 | 09/27 | | |
NCT06690671: A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC |
|
|
| Not yet recruiting | 1/2 | 30 | RoW | Golidocitinib in combination with anti-PD-1 | Shanghai Chest Hospital | Lung Cancer, Non-Small Cell | 06/25 | 06/26 | | |
NCT06757387: Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma |
|
|
| Not yet recruiting | 1/2 | 45 | NA | chidamide and golidocitinib | Peking University Cancer Hospital & Institute | Peripheral T-cell Lymphoma | 12/28 | 12/30 | | |
